Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLC1
- Development stage
- Preclinical
- Lead developer
- Ss. Cyril and Methodius University in Skopje
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
**NLC1** is an experimental nanostructured lipid carrier formulation loaded with *Cannabis sativa* extract containing cannabidiol and cannabidiolic acid. It was developed as a lipid-nanoparticle delivery system intended to improve prolonged release and brain delivery of the cannabis extract for epilepsy. In a preclinical pentylenetetrazole-induced seizure model in mice, the studied lipid nano-carrier formulations, including NLC1, delayed the onset of myoclonic, clonic, and tonic seizures. It is not an approved medicine or a sponsor-designated drug candidate. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36189477/))
- Other names
- Cannabis sativa extract-loaded NLC1
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on NLC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLC1.